sarcoma

(redirected from Soft tissue sarcoma)
Also found in: Dictionary, Medical, Legal, Financial, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to sarcoma

References in periodicals archive ?
Nanobiotix expects to present the results of its Phase II/III trial in soft tissue sarcoma in the first half of 2018.
Furthermore, Halaven was first approved as a treatment for soft tissue sarcoma in the United States in January 2016, and is approved in countries including Japan and in Europe.
A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Prognostic factors for survival in soft tissue sarcoma.
Soft Tissue Sarcoma Diagnosis Distribution by Sampling Modality Sampling Modality Core Needle Incisional Biopsy Biopsy Tumor Type (n - 103) (n - 107) Synovial sarcoma 18 20 Leiomyosarcoma 10 13 Myxofibrosarcoma 14 20 Fibrosarcoma 4 2 Undifferentiated pleomorphic 33 33 sarcoma Pleomorphic sarcoma 11 5 with myogenic features Myofibrosarcoma 0 1 Sarcoma not otherwise specified 13 8 Myxoinflammatory fibroblastic 0 5 sarcoma Table 3.
Long-term prognosis of primary retroperitoneal soft tissue sarcoma," Eur J Surg Oncol 2007, Vol.
Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, has announced an update on its PICASSO 3 trial, a randomized, double-blinded, placebo- controlled Phase 3 trial of palifosfamide for the treatment of metastatic soft tissue sarcoma in the front-line setting.
Ross Houston died of rare soft tissue sarcoma on Friday.
Cotara is also being studied in a Phase I trial for colorectal, pancreas, soft tissue sarcoma and biliary cancers at Stanford University.
Sant Chawla, the principal investigator of CytRx's global Phase 3 clinical trial for soft tissue sarcoma.
M2 PHARMA-October 28, 2016-Philogen announces EC grant of Orphan Drug Designation for treatment of soft tissue sarcoma
The product is intended for the treatment of adults with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.